Adare Pharma Solutions’ Post

The obesity drug market was over $20 billion last year and could reach $131 billion by 2028. That 27% annual growth estimate compares with a prior projection of 13%. It's not hard to see why there is a scramble for assets, and why next generation GLP drugs are on everyone's radar. On that note, Roche are planning on fast tracking their anti-obesity medication they acquired from their Carmot purchase. They are intending to make it to market by 2029, underscoring the difficult of bringing a drug to market quickly (even in this case, it's a Herculean task!). Roche have published impressive results, with patients on the once weekly injection losing an average of 19% body weight before the 6 month mark. https://lnkd.in/g7gPeASC

Thoughts on this? >> Roche details early obesity data from GLP-1/GIP agonist, plans for Phase 2 study this year >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #pharma #productmarketing #healthcare

JP Morgan predictions on obesity drugs. Eli Lilly performs better than Nvidia 🤯 in last 3 years. By 2030, GLP-1s market will cross $100 billion. GLP-1 is for Type 2 Diabetics patients (help reducing sugar level, suppress appetite and calories intake => as a side effect, helps in Obesity)🙏 Currently, Companies enjoy duopoly - 1. Novo Nordisk 2. Eli Lilly Other players are joining the race. Social message 😊: I hope the government regulates it to prevent people from mindlessly following trends for weight reduction. High demand can result in shortages, denying genuine T2D patients access. https://lnkd.in/dj63kCcn

Thoughts on this? >> Roche details early obesity data from GLP-1/GIP agonist, plans for Phase 2 study this year >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #pharmaceutical #productmarketing #biotech

The increasing prevalence of obesity and related metabolic disorders globally has fueled the demand for effective medications like Semaglutide, which not only aids in weight management but also offers benefits in managing diabetes and other metabolic conditions. This strong market outlook underscores the potential impact and significance of Semaglutide in addressing critical health challenges and meeting the needs of a growing patient population. What is your opinion of "Semaglutide's Market Prospects in the Global Pharmaceutical Industry", please feel free to let us know. For more, please take a look at our blog https://lnkd.in/egWcGeqr and let me know if you are interested in our semaglutide.

$LLY anticipates Zepbound approval in Japan by mid-2025, targeting the growing weight loss market. This move could strengthen their global presence in obesity treatments: https://ibn.fm/2RNJp #EliLilly #Pharma #WeightLoss #ObesityTreatment #HealthcareInnovation

The increasing prevalence of obesity and related metabolic disorders globally has fueled the demand for effective medications like Semaglutide, which not only aids in weight management but also offers benefits in managing diabetes and other metabolic conditions. This strong market outlook underscores the potential impact and significance of Semaglutide in addressing critical health challenges and meeting the needs of a growing patient population. What is your opinion of "Semaglutide's Market Prospects in the Global Pharmaceutical Industry", please feel free to let us know. #Semaglutide #api #sinoway

🌟 The Battle for GLP-1 Drug Production: A Crucial Manufacturing Challenge 🌟 Drawing inspiration from the recent Endpoints article titled "The obesity drug race is being fought on the manufacturing floor as GLP-1 rivals make plans to catch leaders," it's clear that there's an urgent need for robust manufacturing solutions within the rapidly expanding GLP-1 sector. Alcami stands ready to aid pharmaceutical firms navigate this fiercely competitive field by offering: 🔹 Over 40 Years of Expertise in CDMO services 🔹 Cutting-Edge Facilities with increased capacity 🔹 Specialization in Sterile Fill-Finish processes for biologics 🔹 Comprehensive Coverage across the nation for uninterrupted service With the growing demand for GLP-1 therapies, allow Alcami to be your dependable ally in enhancing production capabilities and effectively fulfilling patient requirements. 💬 Keen to discover more? Check out the Endpoints News Article! https://gag.gl/mJLA2e #GLP1 #CDMO #PharmaceuticalManufacturing #Alcami #ObesityTreatment

Check out the latest blog post discussing the rising prevalence of obesity and its impact on our society. The article delves into the cultural trends and pharmaceutical interventions surrounding obesity. To read more, click the following link: https://ift.tt/76REb8z

Thoughts on this? >> Eli Lilly obesity drug shortage ending threatens access to compounded tirzepatide >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharma #biotech #pharmaceutical